CLEO Diagnostics Ltd. is a medical diagnostics/devices company which mainly focuses on the development of non-invasive blood based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company developed a three-phased product development strategy that will deliver three related tests for ovarian cancer detection: Triage Test-a pre-surgical test, Recurrence Test-a post-surgical test and Screening Test-a screening test to identify early-stage ovarian cancer. CLEO Diagnostics was founded on November 30, 2021 and is headquartered in Melbourne, Australia.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company